A consortium of strong partners has launched the CARMA FUND I as a new vehicle for the translation of promising early-stage life-science projects: the initiators, Ascenion GmbH, a life-science focused technology transfer company of the LifeScience Foundation and the Goethe-University, Frankfurt am Main with its technology transfer company Innovectis GmbH, together with the European Investment Fund (EIF), the life science company Evotec SE and other investors. The fund will be managed by CARMA FUND Management GmbH, headed by its general partners Christian Leikert and Martin Raditsch. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/carma-fund-i-completes-first-closing-of-eur-47-m-to-accelerate-the-transfer-of-life-science-research-into-practice-6187
Evotec's partner Exscientia reports topline data from EXS-21546 phase 1A study
Evotec’s partner Exscientia plc today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2a receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-exscientia-reports-topline-data-from-exs-21546-phase-1a-study-6185
Evotec enters a drug discovery collaboration with Janssen
Evotec SE announced today that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Evotec’s innovative TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action therapeutic candidates. The agreement was facilitated by Johnson & Johnson Innovation. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-a-drug-discovery-collaboration-with-janssen-6183
Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
Evotec SE today announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price of € 23 m. Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia, Rigenerand is a pioneering company in the field of cGMP manufacturing of cell therapies. The acquisition adds a great team of cell therapy cGMP manufacturing experts to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-adds-cell-therapy-manufacturing-facility-with-acquisition-of-rigenerand-6181
Evotec and Almirall enter into a multi-target alliance in medical dermatology
Evotec SE and Almirall S.A., a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-almirall-enter-into-a-multi-target-alliance-in-medical-dermatology-6179
Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
Evotec SE and Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a partnership in the field of diabetes. Both Companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sernova-announce-exclusive-strategic-partnership-for-ipsc-based-beta-cell-replacement-therapy-to-advance-a-functional-cure-for-diabetes-6177
Evotec SE reports results for the first quarter 2022 and provides corporate update
Evotec SE today announced the financial results and corporate updates for the first quarter 2022: Strong performance leads to significant revenue growth; strong momentum in all business areas; new partnerships based on data-driven precision medicine platforms; guidance for full-year 2022 confirmed Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-quarter-2022-and-provides-corporate-update-6175
Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
Evotec SE announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for an additional 8 years with the goal to further broaden and deepen the strategic alliance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bristol-myers-squibb-extend-and-expand-strategic-partnership-in-protein-degradation-6173
Evotec SE to announce results for the first quarter 2022 on 11 May 2022
Evotec SE will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-announce-results-for-the-first-quarter-2022-on-11-may-2022-6169
Evotec makes strategic equity investment in antibody drug conjugate specialist Tubulis
Evotec SE announced today that the Company has made a strategic equity investment in Tubulis GmbH by participating in the company’s Series B financing round. Based in Munich, Germany, Tubulis specialises in the development of antibody drug conjugates (“ADCs”) by leveraging a set of proprietary technology platforms to develop these highly targeted therapeutics against solid tumours. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-makes-strategic-equity-investment-in-antibody-drug-conjugate-specialist-tubulis-6168